Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Corporate Information (Details Textual)

v3.22.2.2
Note 1 - Corporate Information (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
May 31, 2013
Cash, Cash Equivalents, and Short-Term Investments, Total $ 69,800   $ 69,800      
Net Income (Loss) Attributable to Parent, Total (9,736) $ (16,536) (25,175) $ (36,206)    
Retained Earnings (Accumulated Deficit), Total $ (282,319)   $ (282,319)   $ (257,144)  
Pieris Pharmaceuticals GmbH [Member]            
Business Acquisition, Percentage of Voting Interests Acquired           100.00%